Nifty
:
17097.40
Sensex
:
57908.68
-54.50 (-0.32%)
-305.91 (-0.53%)
Nifty
Sensex
:
:
17097.40
57908.68
-54.50 (-0.32%)
-305.91 (-0.53%)

Zydus Lifesciences Ltd.

Pharmaceuticals & Drugs - Global

Rating :
67/99

BSE: 532321 | NSE: ZYDUSLIFE

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 48,439.03
  • 23.52
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 51,528.13
  • 0.52%
  • 2.81

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 74.98%
  • 0.82%
  • 7.04%
  • FII
  • DII
  • Others
  • 2.51%
  • 13.51%
  • 1.14%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.15
  • 5.01
  • 2.31

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.48
  • 3.32
  • 3.67

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 12.88
  • 5.09
  • 24.13

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 24.32
  • 20.25
  • 23.93

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.67
  • 3.34
  • 3.29

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.11
  • 13.80
  • 14.93

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 22
Dec 21
Var%
Sep 22
Sep 21
Var%
Jun 22
Jun 21
Var%
Mar 22
Mar 21
Var%
Net Sales
4,362.30
3,639.80
19.85%
4,134.70
3,759.80
9.97%
4,072.70
4,001.80
1.77%
3,863.80
3,670.30
5.27%
Expenses
3,406.30
2,888.20
17.94%
3,319.40
2,860.30
16.05%
3,239.70
3,029.90
6.92%
3,146.10
2,820.80
11.53%
EBITDA
956.00
751.60
27.20%
815.30
899.50
-9.36%
833.00
971.90
-14.29%
717.70
849.50
-15.52%
EBIDTM
21.91%
20.65%
19.72%
23.92%
20.45%
24.29%
18.57%
23.15%
Other Income
38.50
60.70
-36.57%
44.40
53.30
-16.70%
65.90
31.60
108.54%
79.10
-30.40
-
Interest
32.80
31.10
5.47%
35.10
30.10
16.61%
34.30
27.30
25.64%
38.50
23.20
65.95%
Depreciation
181.60
177.00
2.60%
181.80
177.30
2.54%
180.70
173.30
4.27%
185.40
175.30
5.76%
PBT
780.10
604.20
29.11%
642.80
858.10
-25.09%
681.00
802.90
-15.18%
572.90
547.50
4.64%
Tax
195.20
109.40
78.43%
137.00
135.70
0.96%
118.40
157.40
-24.78%
109.20
-206.00
-
PAT
584.90
494.80
18.21%
505.80
722.40
-29.98%
562.60
645.50
-12.84%
463.70
753.50
-38.46%
PATM
13.41%
13.59%
12.23%
19.21%
13.81%
16.13%
12.00%
20.53%
EPS
6.16
4.89
25.97%
5.16
29.32
-82.40%
5.06
5.73
-11.69%
3.88
6.63
-41.48%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Net Sales
16,433.50
15,265.20
14,403.50
14,253.10
13,165.60
11,954.50
9,376.50
9,426.80
8,651.30
7,224.00
6,357.70
Net Sales Growth
9.04%
5.98%
1.06%
8.26%
10.13%
27.49%
-0.53%
8.96%
19.76%
13.63%
 
Cost Of Goods Sold
6,109.90
4,757.00
4,094.20
4,243.30
4,141.30
3,656.90
3,065.00
2,673.20
2,814.10
2,412.60
2,036.80
Gross Profit
10,323.60
10,508.20
10,309.30
10,009.80
9,024.30
8,297.60
6,311.50
6,753.60
5,837.20
4,811.40
4,320.90
GP Margin
62.82%
68.84%
71.57%
70.23%
68.54%
69.41%
67.31%
71.64%
67.47%
66.60%
67.96%
Total Expenditure
13,111.50
11,935.20
11,018.20
11,472.90
10,187.20
9,125.90
7,475.00
7,097.30
6,897.40
6,031.20
5,234.00
Power & Fuel Cost
-
299.30
231.60
252.90
231.60
211.40
174.50
155.40
145.40
129.70
124.40
% Of Sales
-
1.96%
1.61%
1.77%
1.76%
1.77%
1.86%
1.65%
1.68%
1.80%
1.96%
Employee Cost
-
2,177.70
2,069.50
2,169.80
1,903.20
1,644.70
1,485.20
1,119.00
1,096.50
974.00
818.40
% Of Sales
-
14.27%
14.37%
15.22%
14.46%
13.76%
15.84%
11.87%
12.67%
13.48%
12.87%
Manufacturing Exp.
-
2,272.30
2,271.40
2,230.00
1,923.20
1,680.40
955.30
1,397.60
1,136.90
936.50
897.30
% Of Sales
-
14.89%
15.77%
15.65%
14.61%
14.06%
10.19%
14.83%
13.14%
12.96%
14.11%
General & Admin Exp.
-
412.50
444.00
582.60
583.40
398.70
466.00
356.40
326.80
302.70
342.20
% Of Sales
-
2.70%
3.08%
4.09%
4.43%
3.34%
4.97%
3.78%
3.78%
4.19%
5.38%
Selling & Distn. Exp.
-
1,467.50
1,358.60
1,468.40
1,033.30
1,129.40
826.40
979.60
1,047.20
980.50
857.50
% Of Sales
-
9.61%
9.43%
10.30%
7.85%
9.45%
8.81%
10.39%
12.10%
13.57%
13.49%
Miscellaneous Exp.
-
548.90
548.90
525.90
371.20
404.40
502.60
416.10
330.50
295.20
857.50
% Of Sales
-
3.60%
3.81%
3.69%
2.82%
3.38%
5.36%
4.41%
3.82%
4.09%
2.48%
EBITDA
3,322.00
3,330.00
3,385.30
2,780.20
2,978.40
2,828.60
1,901.50
2,329.50
1,753.90
1,192.80
1,123.70
EBITDA Margin
20.21%
21.81%
23.50%
19.51%
22.62%
23.66%
20.28%
24.71%
20.27%
16.51%
17.67%
Other Income
227.90
235.40
47.40
117.10
208.50
133.00
147.10
116.60
57.20
85.90
38.40
Interest
140.70
127.00
158.80
341.80
195.80
110.80
63.10
52.80
67.90
118.10
168.70
Depreciation
729.50
713.00
669.60
696.50
598.60
538.80
373.30
292.10
287.30
201.20
184.70
PBT
2,676.80
2,725.40
2,604.30
1,859.00
2,392.50
2,312.00
1,612.20
2,101.20
1,455.90
959.40
808.70
Tax
559.80
511.70
193.60
319.80
530.30
564.40
128.90
177.40
259.40
106.00
118.80
Tax Rate
20.91%
18.03%
8.07%
21.39%
22.26%
24.41%
8.00%
8.45%
17.95%
11.25%
14.69%
PAT
2,117.00
2,195.40
2,154.20
1,147.80
1,801.90
1,713.00
1,453.90
1,890.90
1,148.50
803.60
653.50
PAT before Minority Interest
1,991.10
2,326.40
2,205.60
1,175.60
1,851.80
1,747.60
1,483.00
1,921.30
1,186.10
836.20
689.90
Minority Interest
-125.90
-131.00
-51.40
-27.80
-49.90
-34.60
-29.10
-30.40
-37.60
-32.60
-36.40
PAT Margin
12.88%
14.38%
14.96%
8.05%
13.69%
14.33%
15.51%
20.06%
13.28%
11.12%
10.28%
PAT Growth
-19.08%
1.91%
87.68%
-36.30%
5.19%
17.82%
-23.11%
64.64%
42.92%
22.97%
 
EPS
20.91
21.69
21.28
11.34
17.80
16.92
14.36
18.68
11.35
7.94
6.46

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Shareholder's Funds
16,999.60
12,992.30
10,375.70
10,386.30
8,744.50
6,960.00
5,699.20
4,251.60
3,439.00
2,944.50
Share Capital
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
Total Reserves
16,897.20
12,889.90
10,273.30
10,283.90
8,642.10
6,857.60
5,596.80
4,149.20
3,336.60
2,842.10
Non-Current Liabilities
-193.60
19.40
2,853.90
3,491.10
2,122.20
1,903.30
736.10
1,341.50
1,589.20
1,640.00
Secured Loans
0.00
0.00
1,953.60
2,332.80
200.60
319.60
393.80
664.00
851.40
917.20
Unsecured Loans
362.10
609.50
1,261.00
1,616.90
2,354.50
2,148.80
502.60
486.40
510.80
508.80
Long Term Provisions
325.00
309.50
235.20
184.10
155.90
151.20
120.70
90.40
76.10
66.50
Current Liabilities
7,826.80
7,861.30
8,269.40
7,342.50
6,083.00
5,305.80
3,461.00
3,285.10
2,814.00
2,670.40
Trade Payables
2,137.80
2,205.90
2,044.30
1,922.60
1,888.40
1,547.90
1,308.10
1,090.90
910.80
656.80
Other Current Liabilities
1,967.50
2,166.20
2,126.30
2,033.60
1,484.90
1,212.10
860.70
628.20
708.10
509.20
Short Term Borrowings
3,314.10
3,070.90
3,826.50
3,196.90
2,557.50
2,476.90
1,210.90
1,183.50
902.40
1,257.10
Short Term Provisions
407.40
418.30
272.30
189.40
152.20
68.90
81.30
382.50
292.70
247.30
Total Liabilities
26,687.00
22,810.30
22,833.70
22,512.80
17,140.70
14,325.20
10,032.10
9,047.10
7,986.50
7,374.20
Net Block
12,253.40
12,132.80
12,230.50
12,163.70
6,482.60
5,755.10
3,747.90
3,352.20
3,123.80
3,025.60
Gross Block
17,715.80
17,345.00
16,781.50
15,702.30
9,349.10
8,102.90
5,767.30
5,138.50
4,664.00
4,376.20
Accumulated Depreciation
5,291.80
5,212.20
4,551.00
3,538.60
2,866.50
2,345.80
2,016.80
1,786.30
1,540.20
1,350.60
Non Current Assets
14,438.20
14,094.30
14,118.30
14,014.70
8,911.00
8,302.90
5,751.70
4,820.40
4,548.60
4,182.50
Capital Work in Progress
661.00
783.20
741.50
837.20
1,527.20
1,543.30
950.80
797.90
891.50
735.60
Non Current Investment
934.80
631.20
552.20
443.60
470.90
385.70
217.10
33.20
22.20
21.20
Long Term Loans & Adv.
369.30
323.30
332.00
410.40
300.00
384.70
661.20
637.10
511.10
400.10
Other Non Current Assets
219.70
223.80
262.10
159.80
130.30
234.10
174.70
0.00
0.00
0.00
Current Assets
12,095.20
8,716.00
8,715.40
8,498.10
8,229.70
6,022.30
4,280.40
4,226.70
3,437.90
3,191.70
Current Investments
2,353.20
198.90
212.80
229.90
274.80
49.10
199.10
121.20
64.40
93.30
Inventories
3,719.40
3,236.20
2,789.00
2,688.00
2,385.30
1,803.70
1,337.10
1,535.70
1,367.50
1,213.60
Sundry Debtors
3,340.30
3,127.30
3,663.20
3,950.80
3,206.30
2,277.50
1,746.60
1,588.40
1,133.70
955.10
Cash & Bank
1,106.90
888.30
964.90
548.90
1,314.90
1,543.50
638.70
669.90
548.80
583.80
Other Current Assets
1,575.40
523.90
441.60
496.00
1,048.40
348.50
358.90
311.50
323.50
345.90
Short Term Loans & Adv.
1,382.20
741.40
643.90
584.50
527.70
268.50
234.80
240.80
254.90
279.00
Net Current Assets
4,268.40
854.70
446.00
1,155.60
2,146.70
716.50
819.40
941.60
623.90
521.30
Total Assets
26,533.40
22,810.30
22,833.70
22,512.80
17,140.70
14,325.20
10,032.10
9,047.10
7,986.50
7,374.20

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Cash From Operating Activity
2,104.10
3,293.90
2,931.50
1,281.90
919.30
1,311.70
1,893.50
993.60
902.80
603.40
PBT
5,232.30
2,284.80
1,495.40
2,382.10
2,312.00
1,611.90
2,098.70
1,445.50
942.20
808.70
Adjustment
-2,102.10
1,163.00
1,474.40
539.10
624.30
333.70
249.80
344.50
269.00
315.90
Changes in Working Capital
-351.50
191.10
263.80
-971.70
-1,383.90
-411.20
271.70
-377.00
-20.10
-201.60
Cash after chg. in Working capital
2,778.70
3,638.90
3,233.60
1,949.50
1,552.40
1,534.40
2,620.20
1,413.00
1,191.10
923.00
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-674.60
-345.00
-302.50
-675.40
-602.30
-237.60
-646.00
-386.90
-172.80
-272.00
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.40
7.80
-30.80
14.90
-80.70
-32.50
-115.50
0.00
Cash From Investing Activity
1,154.40
-724.60
-1,012.30
-4,238.70
-973.70
-2,871.90
-863.50
-464.70
-438.00
-682.30
Net Fixed Assets
-490.20
-462.80
-289.60
-1,652.30
-600.20
-557.40
-531.50
-271.50
-239.50
-646.90
Net Investments
1,352.60
-66.50
-2,208.90
-577.10
305.60
-1,606.20
-108.40
-651.40
-277.80
-67.70
Others
292.00
-195.30
1,486.20
-2,009.30
-679.10
-708.30
-223.60
458.20
79.30
32.30
Cash from Financing Activity
-868.30
-2,547.70
-1,528.20
1,884.60
51.50
2,315.80
-934.80
-351.10
-528.70
285.80
Net Cash Inflow / Outflow
2,390.20
21.60
391.00
-1,072.20
-2.90
755.60
95.20
177.80
-63.90
206.90
Opening Cash & Equivalents
1,087.20
1,177.70
778.80
1,589.70
1,592.60
837.00
737.90
612.60
676.50
469.60
Closing Cash & Equivalent
3,460.10
1,087.20
1,177.70
778.80
1,589.70
1,592.60
837.00
790.40
612.60
676.50

Financial Ratios

Consolidated /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Book Value (Rs.)
166.01
126.88
101.33
101.43
85.40
67.97
55.66
41.52
33.58
28.75
ROA
9.40%
9.66%
5.18%
9.34%
11.11%
12.18%
20.14%
13.93%
10.89%
10.00%
ROE
15.51%
18.88%
11.32%
19.36%
22.26%
23.43%
38.62%
30.85%
26.20%
24.95%
ROCE
15.30%
14.23%
10.02%
15.89%
18.41%
16.50%
28.60%
23.21%
17.67%
18.21%
Fixed Asset Turnover
1.69
1.69
0.88
1.05
1.38
1.38
1.76
1.80
1.63
1.55
Receivable days
39.81
42.92
97.49
99.21
83.37
76.72
63.29
56.38
51.71
52.78
Inventory Days
42.81
38.08
70.13
70.33
63.69
59.88
54.52
60.13
63.89
64.82
Payable days
166.64
189.45
64.85
68.81
68.11
74.18
65.30
55.05
49.83
43.54
Cash Conversion Cycle
-84.02
-108.45
102.77
100.73
78.94
62.42
52.51
61.46
65.78
74.05
Total Debt/Equity
0.25
0.35
0.77
0.76
0.62
0.75
0.43
0.62
0.79
0.99
Interest Cover
23.35
16.11
5.38
13.17
21.87
26.55
40.75
22.29
8.98
5.79

Annual Reports:

FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013

News Update:


  • Zydus Lifesciences’s arm gets USFDA’s approval for Tofacitinib Tablets
    22nd Mar 2023, 10:17 AM

    The drug will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad

    Read More
  • Zydus Lifesciences gets orphan drug designation for ZYIL1 in treatment of patients with CAPS
    21st Mar 2023, 11:20 AM

    ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates

    Read More
  • Zydus Lifesciences gets USFDA’s final approval for Olanzapine Orally Disintegrating Tablets
    11th Mar 2023, 15:09 PM

    The products will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad (India)

    Read More
  • Zydus Lifesciences gets USFDA's final nod for Erythromycin Tablets
    9th Mar 2023, 16:59 PM

    Erythromycin Tablets USP, 250 mg and 500 mg had annual sales of $25.1 million in the United States

    Read More
  • Zydus Lifesciences gets USFDA’s final approval for Lenalidomide Capsules
    8th Mar 2023, 09:39 AM

    Lenalidomide may lessen the need for blood transfusions

    Read More
  • Zydus Lifesciences gets USFDA’s final approval for Vigabatrin for oral solution
    3rd Mar 2023, 16:00 PM

    The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya

    Read More
  • Zydus Lifesciences gets USFDA’s nod for Acyclovir Cream
    2nd Mar 2023, 14:58 PM

    The drug will be manufactured at the group’s topical manufacturing facility at Changodar, Ahmedabad (India)

    Read More
  • Zydus Lifesciences gets USFDA’s approval for Apixaban Tablets
    1st Mar 2023, 09:49 AM

    The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad

    Read More
  • Zydus Lifesciences gets USFDA’s final approval for Pitavastatin Tablets
    24th Feb 2023, 15:40 PM

    The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya

    Read More
  • Zydus Lifesciences’ arm gets tentative approval for Canagliflozin, Metformin Hydrochloride Tablets
    20th Feb 2023, 10:23 AM

    Canagliflozin and Metformin Hydrochloride Tablets had annual sales of $49.4 million in the United States

    Read More
  • Zydus Lifesciences’ arm gets tentative approval for Gabapentin Tablets from USFDA
    20th Feb 2023, 09:22 AM

    Gabapentin tablets are indicated for the management of Postherpetic Neuralgia

    Read More
  • Zydus Lifesciences gets final nod for Sirolimus Tablets from USFDA
    17th Feb 2023, 10:57 AM

    Sirolimus Tablets had annual sales of $69mn in the United States

    Read More
  • Zydus Lifesciences gets tentative approval from USFDA for Bosentan Tablets for oral suspension
    15th Feb 2023, 15:52 PM

    The drug will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad

    Read More
  • Zydus Lifesciences gets USFDA’s tentative approval for Canagliflozin Tablets
    15th Feb 2023, 15:08 PM

    Canagliflozin Tablets had annual sales of $660 million in the United States

    Read More
  • Zydus Lifesciences - Quarterly Results
    3rd Feb 2023, 12:44 PM

    Read More
  • USFDA conducts inspection at Zydus Lifesciences’ manufacturing facility in Ahmedabad
    27th Jan 2023, 14:25 PM

    The inspection concluded with NIL observations

    Read More
  • Zydus Lifesciences’ arm gets tentative approval to market Levomilnacipran Extended-Release Capsules
    16th Jan 2023, 09:23 AM

    Levomilnacipran Extended-Release Capsules had annual sales of $85 million in the United States

    Read More
  • Zydus Lifesciences’ arm gets USFDA’s final approval to market Brexpiprazole Tablets
    12th Jan 2023, 10:50 AM

    The group now has 340 approvals and has so far filed over 431 ANDAs since the commencement of the filing process in FY 2003-04

    Read More
  • Zydus Lifesciences gets USFDA’s final approval for Febuxostat Tablets
    10th Jan 2023, 14:52 PM

    The group now has 340 approvals and has so far filed over 431 ANDAs since the commencement of the filing process in FY 2003-04

    Read More
  • Zydus Lifesciences’ arm launches Topiramate Extended-Release Capsules
    6th Jan 2023, 12:58 PM

    Zydus is the first company to receive final approval and launch Topiramate Extended-Release Capsules in the United States

    Read More
  • Zydus Lifesciences gets final approval from USFDA for Triazolam Tablets
    30th Dec 2022, 15:56 PM

    The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad, India

    Read More
  • Zydus Lifesciences’ arm gets final approval from USFDA for Selexipag Tablets
    22nd Dec 2022, 14:45 PM

    The group now has 338 approvals and has so far filed over 431 ANDAs since the commencement of the filing process in FY 2003-04

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.